DeepMed Research

Ceralasertib

Generic Name: Ceralasertib

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄N_₆O_₂S

CAS Number: 1352226-88-0

Unique Ingredient Identifier: 85RE35306Z

Background: Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).

Clinical Trials

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Adavosertib
Drug: Olaparib
Drug: Ceralasertib

First Posted Date: 2018-07-06

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT03579316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Phase 1

Completed

Conditions: Non-hodgkin's Lymphoma
Diffuse Large B Cell Lymphoma
NHL
DLBCL

Interventions: Drug: AZD9150
Drug: Acalabrutinib
Drug: AZD6738
Drug: Hu5F9-G4
Drug: AZD5153
Drug: Rituximab

First Posted Date: 2018-05-17

Last Posted Date: 2022-08-15

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 30

Registration Number: NCT03527147

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: High Grade Serous Carcinoma

Interventions: Drug: Olaparib Pill
Drug: AZD6738

First Posted Date: 2018-03-12

Last Posted Date: 2025-03-19

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 123

Registration Number: NCT03462342

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

Phase 2

Completed

Conditions: SCLC

Interventions: Drug: AZD6738
Drug: Olaparib

First Posted Date: 2018-02-09

Last Posted Date: 2021-02-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 26

Registration Number: NCT03428607

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: AZD6738 (ceralasertib)
Drug: AZD6738 (ceralasertib) 7 days monotherapy
Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)
Drug: trastuzumab deruxtecan
Drug: Olaparib
Drug: AZD9150
Drug: Vistusertib
Drug: AZD6738
Drug: Oleclumab
Drug: cediranib

First Posted Date: 2017-11-07

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 527

Registration Number: NCT03334617

Locations: 🇪🇸
Research Site, Sevilla, Spain

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2

Active, not recruiting

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

First Posted Date: 2017-11-06

Last Posted Date: 2025-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 273

Registration Number: NCT03330847

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Ceralasertib
Drug: Acalabrutinib

First Posted Date: 2017-11-01

Last Posted Date: 2025-03-03

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 11

Registration Number: NCT03328273

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

Phase 2

Conditions: Advanced Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Olaparib
Drug: AZD5363
Drug: AZD6738
Drug: Neratinib

First Posted Date: 2017-06-09

Last Posted Date: 2019-01-22

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 1150

Registration Number: NCT03182634

Locations: 🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧
Royal Marsden Hosital, Sutton, England, United Kingdom
🇬🇧
Clatterbridge Cancer Centre, Liverpool, United Kingdom

and more 16 locations

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Olaparib
Drug: Ceralasertib

First Posted Date: 2017-01-16

Last Posted Date: 2021-08-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT03022409

Locations: 🇨🇳
Research Site, Taipei, Taiwan

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

First Posted Date: 2016-06-24

Last Posted Date: 2025-01-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 455

Registration Number: NCT02813135

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU Pellegrin, Bordeaux, France

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy